Nishida S, Tada R, Nishiwaki T, Takahashi R, Yanagawa S, Mitamura K
Sangyo Igaku. 1982 May;24(3):253-64. doi: 10.1539/joh1959.24.253.
This report covers 7-year follow-up studies on 35 HBs Ag carriers whose anti-HBc titer levels were 10 (log 2) or more and who had normal liver functions at the start of the studies, when 9 of them (25.7%) were HBe Ag positive, 24 (68.6%) anti-HBe positive and 2 (5.7%) negative to both. 1. There was no significant difference in the incidence of abnormal SGPT levels as a whole between HBe Ag positives and anti-HBe positives. But abnormally high SGPT levels of 100 KU or more were observed at a higher percentage among HBe Ag positives (4/9. 44.4%) than among anti-HBe positives (1/24. 4.2%. p less than 0.02). 2. Based on the results of the 7-year studies, all cases were classified into six clinical stages. HBe Ag positives were divided into three groups by the stage with different SGPT levels: 5 cases (15.2%) whose SGPT leves never rose above 50 KU were classified as Stage 1; 3 cases with chronic active hepatitis (9.6%) whose highest SGPT levels were over 200 KU (2 new cases and 1 case with a relapse of chronic inactive hepatitis) as Stage 2 and 1 case (3.0%) seroconverted to anti-HBe positive following an acute relapse of chronic inactive hepatitis as Stage 3. Anti-HBe positives were divided into another three groups similarly according to their mean HBs Ag titer levels: 6 cases (18.2%) whose mean HBs Ag titer levels ranged from 10 to 13 (log 2) were classified as Stage 4; 13 cases (39.4%) whose mean HBs Ag titer levels ranged from 6 to 9 as Stage 5 and 5 cases (15.2%), including 2 cases turned negative to HBs Ag, whose mean HBs Ag titer levels were below 5 as Stage 6. The average age of each group increased wth its clinical stage, namely, 32.6 in Stage 1, 34.3 in Stage 2, 33.0 in Stage 3, 34.5 in Stage 4 and 37.0 in Stage 5, but the average age in Stage 6 was 29.0. 3. All HBe Ag positives showed fluctuations in HBs Ag titer levels. The fluctuations were particularly noteworthy among cases with chronic active hepatitis in Stage 2 during an acute relapse. The HBs Ag titers rose just before the acute relapses in a case of chronic active hepatitis when SGPT levels went over 200 KU. This suggested a proliferation of the virus. On the other hand, in anti-HBe positives, a decrement of the virus was suggested by the fact that an increasing proportion of cases showed their HBs Ag titer levels to fluctuate or to become lower with the progress of stages (p less than 0.05) and two cases turned negative to HBs Ag as plotted in Stage 6. And the proportion of cases with abnormal SGPT levels decreased with the progress of stages (p less than 0.05). One case whose SGPT level was 125 KU, highest among anti-HBe positives, followed the clinical course of chronic inactive hepatitis and lowered in HBs Ag titer. 4. Between HBe Ag and anti-HBe cases, there were considerable differences in the occurrence of liver disturbances and their clinical courses...
本报告涵盖了对35例乙肝表面抗原(HBs Ag)携带者的7年随访研究,这些携带者的抗乙肝核心抗体(anti-HBc)滴度水平为10(log2)或更高,且在研究开始时肝功能正常,其中9例(25.7%)为乙肝e抗原(HBe Ag)阳性,24例(68.6%)抗-HBe阳性,2例(5.7%)两者均为阴性。1. HBe Ag阳性者和抗-HBe阳性者总体上谷丙转氨酶(SGPT)水平异常的发生率无显著差异。但SGPT水平异常升高至100 KU或更高的情况在HBe Ag阳性者中所占百分比(4/9,44.4%)高于抗-HBe阳性者(1/24,4.2%,p<0.02)。2. 根据7年研究结果,所有病例被分为六个临床阶段。HBe Ag阳性者根据SGPT水平阶段分为三组:5例(15.2%)SGPT水平从未超过50 KU的被归类为1期;3例慢性活动性肝炎患者(9.6%),其最高SGPT水平超过200 KU(2例新发病例和1例慢性非活动性肝炎复发病例)为2期,1例(3.0%)在慢性非活动性肝炎急性复发后血清转化为抗-HBe阳性为3期。抗-HBe阳性者根据其平均HBs Ag滴度水平类似地分为另外三组:6例(18.2%)平均HBs Ag滴度水平在10至13(log2)之间的被归类为4期;13例(39.4%)平均HBs Ag滴度水平在6至9之间的为5期,5例(15.2%),包括2例HBs Ag转阴的,平均HBs Ag滴度水平低于5的为6期。每组的平均年龄随临床阶段增加,即1期为32.6岁,2期为34.3岁,3期为33.0岁,4期为34.5岁,5期为37.0岁,但6期的平均年龄为29.0岁。3. 所有HBe Ag阳性者的HBs Ag滴度水平均有波动。在2期慢性活动性肝炎病例急性复发期间,这种波动尤为显著。在一例慢性活动性肝炎患者中,当SGPT水平超过200 KU时,HBs Ag滴度在急性复发前升高。这提示病毒增殖。另一方面,在抗-HBe阳性者中,随着阶段进展,越来越多的病例显示其HBs Ag滴度水平波动或降低(p<0.05),且有2例在6期时HBs Ag转阴,提示病毒量减少。并且SGPT水平异常的病例比例随阶段进展而降低(p<0.05)。抗-HBe阳性者中SGPT水平最高为125 KU的一例,遵循慢性非活动性肝炎的临床病程,HBs Ag滴度降低。4. HBe Ag阳性和抗-HBe阳性病例之间,在肝脏病变的发生及其临床病程方面存在相当大的差异……